Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)

Summary

The goal of this clinical research study is to learn if pracinostat, when given in combination with ruxolitinib, can help to control myelofibrosis (MF). The safety of this drug combination will also be studied. This is an investigational study. Pracinostat is not FDA-approved or commercially available. It is currently being used for research purposes only. Ruxolitinib is FDA-approved and commercially available to treat MF. The study doctor can explain how the study drugs are designed to work. Up to 25 participants will be enrolled in this study. All will take part at MD Anderson.

Timeline

Start

2015-01-12

Primary completion

2018-06-01

Completion

2018-06-01

Drugs

Indications